$2.28
-0.31 (-11.97%)
Open$2.56
Previous Close$2.59
Day High$2.58
Day Low$2.25
52W High$31.48
52W Low$20.65
Volume—
Avg Volume553.4K
Market Cap6.83M
P/E Ratio17.83
EPS$1.53
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+1,155.7% upside
Current
$2.28
$2.28
Target
$28.63
$28.63
$25.08
$28.63 avg
$44.18
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.38M | 3.56M | 2.77M |
| Net Income | 377.1K | 452.9K | 261.8K |
| Profit Margin | 11.2% | 12.7% | 9.5% |
| EBITDA | 421.0K | 509.0K | 375.7K |
| Free Cash Flow | 454.1K | 445.4K | 284.4K |
| Rev Growth | -0.5% | +0.2% | +7.6% |
| Debt/Equity | 0.48 | 0.51 | 0.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |